Australia markets closed

ALLK Jan 2024 10.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 08:32AM EST. Market open.
Full screen
Previous close0.0500
Expiry date2024-01-19
Day's range0.0500 - 0.0500
Contract rangeN/A
Open interest4
  • GlobeNewswire

    Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

    SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023. Recent Allakos Events Completed enrollment in both the Phase 2 study of subcutaneous lirentelimab in patients with atopic dermatitis and the Phase 2b study of subcutaneous

  • Simply Wall St.

    Following a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional owners

    Key Insights Given the large stake in the stock by institutions, Allakos' stock price might be vulnerable to their...

  • Motley Fool

    Why Shares of Allakos Are Up Wednesday

    Shares of clinical-stage biotech company Allakos (NASDAQ: ALLK) were up more than 15% as of 11:40 a.m. on Wednesday. Despite the rise, Allakos' stock is still down more than 70% so far this year. Allakos focuses on monoclonal antibodies to trigger responses in the body's immune cells to treat various conditions, including allergies, and inflammatory and proliferative diseases.